NASDAQ:SLRX
Salarius Pharmaceuticals Inc. Stock News
$0.490
+0.0318 (+6.94%)
At Close: May 16, 2024
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference
08:01am, Thursday, 17'th Feb 2022
HOUSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedi
Salarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal
01:40pm, Thursday, 13'th Jan 2022 Benzinga
Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) has agreed to acquire an oral, small molecule targeted protein degradation portfolio against cancer from DeuteRx LLC . The acquisition includes a lead drug candidate that Salarius has renamed SP-3164 (formerly DRX-164). "This strategic acquisition is a transformative event for Salarius that significantly expands our development pipeline while building upon the momentum of our Full story available on Benzinga.com
HOUSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumor
Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
08:31am, Wednesday, 15'th Dec 2021
HOUSTON, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedi
Salarius Pharmaceuticals (SLRX) CEO David Arthur on Q3 2021 Results - Earnings Call Transcript
02:35pm, Sunday, 07'th Nov 2021
Salarius Pharmaceuticals (SLRX) CEO David Arthur on Q3 2021 Results - Earnings Call Transcript
Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress
08:01am, Tuesday, 26'th Oct 2021
Conference Call and Live Audio Webcast Scheduled for Thursday, November 4, 2021, 5:00 p.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, November 4, 2021, 5:00 p.m. ET
HOUSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric canc
Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference
08:01am, Tuesday, 05'th Oct 2021
HOUSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedi
HOUSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric can
Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas
07:01am, Tuesday, 28'th Sep 2021
HOUSTON, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, ped
Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership
07:33am, Wednesday, 22'nd Sep 2021
HOUSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedi
Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index
07:33am, Monday, 20'th Sep 2021
HOUSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, ped
Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
08:03am, Wednesday, 15'th Sep 2021
HOUSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, ped
Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
08:13am, Wednesday, 08'th Sep 2021
HOUSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, ped
Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational
02:00pm, Thursday, 12'th Aug 2021
HOUSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedi
